Xenograft as in vivo experimental model

Manuela Porru, Luca Pompili, Carla Caruso, Carlo Leonetti

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The identification of experimental models that recapitulate human cancers designed to predict patient clinical response to therapies is a major break in oncology. Cancer stem cells (CSCs) represent a small tumor cell population responsible for drug resistance, where their effective killing may lead to identifying better treatment options. While the CSCs hypothesis highlights the need for a specific tumor target, patient-derived xenografts (PDXs) should also be considered for drug development as they better represent tumor heterogeneity and the environment in which a tumor develops.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages97-105
Number of pages9
DOIs
Publication statusPublished - Jan 1 2018

Publication series

NameMethods in Molecular Biology
Volume1692
ISSN (Print)1064-3745

Fingerprint

Heterografts
Theoretical Models
Neoplastic Stem Cells
Neoplasms
Drug Resistance
Therapeutics
Pharmaceutical Preparations
Population

Keywords

  • Heterogeneity
  • Immunosuppressed mice
  • Patient-derived xenografts
  • Predictive model
  • Stroma
  • Transplantation assay
  • Tumorigenicity

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Porru, M., Pompili, L., Caruso, C., & Leonetti, C. (2018). Xenograft as in vivo experimental model. In Methods in Molecular Biology (pp. 97-105). (Methods in Molecular Biology; Vol. 1692). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-7401-6_9

Xenograft as in vivo experimental model. / Porru, Manuela; Pompili, Luca; Caruso, Carla; Leonetti, Carlo.

Methods in Molecular Biology. Humana Press Inc., 2018. p. 97-105 (Methods in Molecular Biology; Vol. 1692).

Research output: Chapter in Book/Report/Conference proceedingChapter

Porru, M, Pompili, L, Caruso, C & Leonetti, C 2018, Xenograft as in vivo experimental model. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 1692, Humana Press Inc., pp. 97-105. https://doi.org/10.1007/978-1-4939-7401-6_9
Porru M, Pompili L, Caruso C, Leonetti C. Xenograft as in vivo experimental model. In Methods in Molecular Biology. Humana Press Inc. 2018. p. 97-105. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-7401-6_9
Porru, Manuela ; Pompili, Luca ; Caruso, Carla ; Leonetti, Carlo. / Xenograft as in vivo experimental model. Methods in Molecular Biology. Humana Press Inc., 2018. pp. 97-105 (Methods in Molecular Biology).
@inbook{efe795d79f5340c9a1a8fd3f17ab0b1b,
title = "Xenograft as in vivo experimental model",
abstract = "The identification of experimental models that recapitulate human cancers designed to predict patient clinical response to therapies is a major break in oncology. Cancer stem cells (CSCs) represent a small tumor cell population responsible for drug resistance, where their effective killing may lead to identifying better treatment options. While the CSCs hypothesis highlights the need for a specific tumor target, patient-derived xenografts (PDXs) should also be considered for drug development as they better represent tumor heterogeneity and the environment in which a tumor develops.",
keywords = "Heterogeneity, Immunosuppressed mice, Patient-derived xenografts, Predictive model, Stroma, Transplantation assay, Tumorigenicity",
author = "Manuela Porru and Luca Pompili and Carla Caruso and Carlo Leonetti",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-7401-6_9",
language = "English",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "97--105",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Xenograft as in vivo experimental model

AU - Porru, Manuela

AU - Pompili, Luca

AU - Caruso, Carla

AU - Leonetti, Carlo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The identification of experimental models that recapitulate human cancers designed to predict patient clinical response to therapies is a major break in oncology. Cancer stem cells (CSCs) represent a small tumor cell population responsible for drug resistance, where their effective killing may lead to identifying better treatment options. While the CSCs hypothesis highlights the need for a specific tumor target, patient-derived xenografts (PDXs) should also be considered for drug development as they better represent tumor heterogeneity and the environment in which a tumor develops.

AB - The identification of experimental models that recapitulate human cancers designed to predict patient clinical response to therapies is a major break in oncology. Cancer stem cells (CSCs) represent a small tumor cell population responsible for drug resistance, where their effective killing may lead to identifying better treatment options. While the CSCs hypothesis highlights the need for a specific tumor target, patient-derived xenografts (PDXs) should also be considered for drug development as they better represent tumor heterogeneity and the environment in which a tumor develops.

KW - Heterogeneity

KW - Immunosuppressed mice

KW - Patient-derived xenografts

KW - Predictive model

KW - Stroma

KW - Transplantation assay

KW - Tumorigenicity

UR - http://www.scopus.com/inward/record.url?scp=85030778022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030778022&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-7401-6_9

DO - 10.1007/978-1-4939-7401-6_9

M3 - Chapter

C2 - 28986890

AN - SCOPUS:85030778022

T3 - Methods in Molecular Biology

SP - 97

EP - 105

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -